Reduction of Adverse Events With Phosphodiesterase 5 Inhibitors Post LVAD Implantation: Is It Time for a Randomized Trial?

Starling, Randall C; Xanthopoulos, Andrew; Nissen, Steven E; Triposkiadis, Filippos

Starling, Randall C; Xanthopoulos, Andrew; Nissen, Steven E; Triposkiadis, Filippos.

Affiliation

Starling RC; Kaufman Center for Heart Failure Treatment and Recovery, Heart Vascular and Thoracic Institute, Cleveland, Ohio. Electronic address: starlir@ccf.org.
Xanthopoulos A; University General Hospital of Larissa, Department of Cardiology, Larissa, Greece.
Nissen SE; Cleveland Clinic Coordinating Center for Clinical Research, Department of Cardiovascular Medicine, Heart Vascular and Thoracic Institute, Cleveland, Ohio.
Triposkiadis F; University General Hospital of Larissa, Department of Cardiology, Larissa, Greece.

J Card Fail ; 28(12): 1733-1737, 2022 12.

Article in En | MEDLINE | ID: mdl-35690316

Subject(s)

Heart Failure; Heart Transplantation; Heart-Assist Devices; Humans; Heart Failure/epidemiology; Phosphodiesterase 5 Inhibitors/adverse effects; Tissue Donors; Heart-Assist Devices/adverse effects; Retrospective Studies; Treatment Outcome

Key words

Phosphodiesterase 5 inhibitors; left ventricular assist devices; mortality; stroke; thrombosis

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Heart-Assist Devices / Heart Transplantation / Heart Failure Type of study: Clinical_trials / Observational_studies Limits: Humans Language: En Journal: J Card Fail Journal subject: CARDIOLOGIA Year: 2022 Type: Article

Fulltext

XML

PubMed Links

Search on Google